TW201722422A - 用於治療癌症之合理組合療法 - Google Patents

用於治療癌症之合理組合療法 Download PDF

Info

Publication number
TW201722422A
TW201722422A TW105132272A TW105132272A TW201722422A TW 201722422 A TW201722422 A TW 201722422A TW 105132272 A TW105132272 A TW 105132272A TW 105132272 A TW105132272 A TW 105132272A TW 201722422 A TW201722422 A TW 201722422A
Authority
TW
Taiwan
Prior art keywords
cancer
protein
hsp90
administered
inhibitor
Prior art date
Application number
TW105132272A
Other languages
English (en)
Chinese (zh)
Inventor
蓋比拉 齊席斯
東尼 塔爾頓
麗莎 雪沙塔
約翰 可倫
艾瑞卡 達加瑪 果美斯
安娜 羅迪那
Original Assignee
美國紀念斯隆-凱特琳癌症中心
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美國紀念斯隆-凱特琳癌症中心 filed Critical 美國紀念斯隆-凱特琳癌症中心
Publication of TW201722422A publication Critical patent/TW201722422A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW105132272A 2015-10-05 2016-10-05 用於治療癌症之合理組合療法 TW201722422A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562237470P 2015-10-05 2015-10-05

Publications (1)

Publication Number Publication Date
TW201722422A true TW201722422A (zh) 2017-07-01

Family

ID=57145064

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105132272A TW201722422A (zh) 2015-10-05 2016-10-05 用於治療癌症之合理組合療法

Country Status (14)

Country Link
US (1) US20180280397A1 (https=)
EP (1) EP3359196B1 (https=)
JP (1) JP7132848B2 (https=)
KR (1) KR20180058824A (https=)
CN (1) CN108472376A (https=)
AU (1) AU2016336351A1 (https=)
BR (1) BR112018006572A2 (https=)
CA (1) CA3000851A1 (https=)
EA (1) EA201890623A1 (https=)
IL (1) IL258494A (https=)
MA (1) MA47474A (https=)
MX (1) MX2018004112A (https=)
TW (1) TW201722422A (https=)
WO (1) WO2017062520A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI882783B (zh) * 2023-05-02 2025-05-01 國立中央大學 偵測轉譯後修飾之方法、系統及電腦可讀取媒體

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016008418A (es) 2013-12-23 2017-01-11 Memorial Sloan Kettering Cancer Center Metodos y reactivos para el radiomarcaje.
CN110090303B (zh) * 2019-05-07 2022-09-16 浙江大学 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途
CN112641949A (zh) * 2021-01-11 2021-04-13 深圳市人民医院(深圳市呼吸疾病研究所) 一种含有pi3k抑制剂的药物组合物及其应用
CN116813622B (zh) * 2023-05-19 2026-02-03 中国科学院基础医学与肿瘤研究所(筹) 一种基于分子伴侣hsp90介导的靶向降解gpx4的嵌合体及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2426762A1 (en) 2000-11-02 2002-05-10 Sloan-Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US10336757B2 (en) 2006-06-30 2019-07-02 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of HSP90
KR101906146B1 (ko) 2009-08-17 2018-10-10 메모리얼 슬로안-케터링 캔서 센터 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법
WO2011044394A1 (en) 2009-10-07 2011-04-14 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
ES2647889T3 (es) 2011-04-05 2017-12-27 Sloan-Kettering Institute For Cancer Research Inhibidores de la Hsp90
WO2012138894A1 (en) 2011-04-05 2012-10-11 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
DK2729806T3 (en) 2011-07-08 2017-05-15 Sloan-Kettering Inst For Cancer Res APPLICATIONS OF MARKED HSP90 INHIBITORS
JP6539275B2 (ja) 2013-08-16 2019-07-03 メモリアル スローン ケタリング キャンサー センター 選択的ｇｒｐ９４阻害剤およびその使用
KR102461419B1 (ko) 2014-05-13 2022-11-02 메모리얼 슬로안 케터링 캔서 센터 Hsp70 조정물질 및 이의 제조 및 이용 방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI882783B (zh) * 2023-05-02 2025-05-01 國立中央大學 偵測轉譯後修飾之方法、系統及電腦可讀取媒體

Also Published As

Publication number Publication date
KR20180058824A (ko) 2018-06-01
BR112018006572A2 (pt) 2018-10-09
WO2017062520A1 (en) 2017-04-13
CN108472376A (zh) 2018-08-31
JP7132848B2 (ja) 2022-09-07
JP2018537519A (ja) 2018-12-20
MA47474A (fr) 2019-12-25
IL258494A (en) 2018-05-31
EA201890623A1 (ru) 2018-09-28
CA3000851A1 (en) 2017-04-13
EP3359196A1 (en) 2018-08-15
EP3359196B1 (en) 2022-03-16
MX2018004112A (es) 2018-06-20
AU2016336351A1 (en) 2018-05-10
US20180280397A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
Halder et al. Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?
US20230330243A1 (en) Combination of antibody-drug conjugate and atr inhibitor
CN105873592B (zh) 用于治疗癌症的组合疗法
US20230256110A1 (en) Combination of antibody-drug conjugate and atm inhibitor
TW201032796A (en) Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor
KR20180035905A (ko) Bet 브로모도메인 억제제에 대한 저항성의 메카니즘
TW201722422A (zh) 用於治療癌症之合理組合療法
BR112017015576A2 (en) method for cancer treatment, article, method for monitoring, method for optimizing therapeutic efficacy, method for identifying a biomarker, use, therapeutic combination, combination for use and product
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
US20250339549A1 (en) Methods for the detection and treatment of non-small-cell lung cancer
Huang et al. Synergistic antitumor activity of pro‐apoptotic agent PAC‐1 with cisplatinum by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299
US9566334B2 (en) Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
EP4582104A1 (en) Combination drug
WO2025082484A1 (zh) 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者
CN121969391A (zh) 上调p53蛋白表达或激活p53功能的药物与DNA烷化剂联用治疗癌症
HK1259690B (en) Rational combination therapy for the treatment of cancer
HK1259690A1 (en) Rational combination therapy for the treatment of cancer
Knickelbein Mechanisms and Novel Therapeutic Approaches for KRAS-Mediated Resistance to Anti-EGFR Therapy in Colorectal Cancer Cells
JP2022023033A (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
Stanley Exploiting Novel Interactions With Parp1 In Dna Repair Proficient Human Breast Cancers
Gerrard Modulation of P-glycoprotein by Zosuquidar Trihydrochloride